Page last updated: 2024-11-04
terazosin and Sepsis
terazosin has been researched along with Sepsis in 1 studies
Terazosin: induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia
Sepsis: Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Chen, X | 1 |
| Zhao, C | 1 |
| Li, X | 2 |
| Wang, T | 1 |
| Li, Y | 1 |
| Cao, C | 1 |
| Ding, Y | 1 |
| Dong, M | 1 |
| Finci, L | 1 |
| Wang, JH | 1 |
| Liu, L | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessing Target Engagement of Terazosin in Healthy Adults[NCT04551040] | Phase 1 | 18 participants (Anticipated) | Interventional | 2021-03-26 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Other Studies
1 other study available for terazosin and Sepsis
| Article | Year |
|---|---|
Terazosin activates Pgk1 and Hsp90 to promote stress resistance.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Apoptosis; Cells, Cultured; Cytokines; HSP90 Heat- | 2015 |